Company / Revenue per Share
IGC Pharma, Inc. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.02
FY2025
5-year range
$0.01 / $0.10
FY2021-FY2025
Trend
-8.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share has fluctuated over the past 10 years, ranging from $0.01 in FY2023 to $5.91 in FY2016.
Based on SEC 10-K filings.
0.02 in FY2025 with a 5-year CAGR of -34.4%.
Improved from $0.01 to $0.02 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -5.8%
- 5-Year CAGR
- -34.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, revenue per share decreased 8.4% year-over-year.
- Peak revenue per share was recorded in FY2016.
- Lowest revenue per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.02 | -8.4% |
| FY2024 | $0.02 | +120.7% |
| FY2023 | $0.01 | -58.6% |
| FY2022 | $0.02 | -81.9% |
| FY2021 | $0.10 | -20.0% |
| FY2020 | $0.13 | +81.7% |
| FY2019 | $0.07 | +247.3% |
| FY2018 | $0.02 | -92.5% |
| FY2017 | $0.27 | -95.4% |
| FY2016 | $5.91 | +237.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026